{"id":29493,"date":"2025-10-28T11:58:59","date_gmt":"2025-10-28T15:58:59","guid":{"rendered":"https:\/\/www.mesotheliomahope.com\/?p=29493"},"modified":"2025-12-04T21:17:31","modified_gmt":"2025-12-05T02:17:31","slug":"new-mesothelioma-keytruda-injection-takes-only-1-minute","status":"publish","type":"post","link":"https:\/\/www.mesotheliomahope.com\/blog\/new-mesothelioma-keytruda-injection-takes-only-1-minute\/","title":{"rendered":"FDA Approves Faster Keytruda\u00ae Injections for Mesothelioma Patients"},"content":{"rendered":"

In 2020, the U.S. Food and Drug Administration (FDA) approved Keytruda\u00ae (pembrolizumab)<\/a> for the treatment of mesothelioma, a rare and aggressive cancer caused by asbestos exposure.<\/p>\n

At the time, Keytruda was administered as an intravenous infusion, which could take more than 30 minutes<\/strong> per treatment. While effective, the infusion process required careful scheduling, longer clinic visits, and additional time for monitoring.<\/p>\n

Now, the FDA has approved a new method that allows mesothelioma patients to receive their treatment in about 1 minute<\/strong>, dramatically reducing the time spent in a clinic or hospital. The injection also makes treatment more convenient and less disruptive to patients\u2019 daily lives.<\/p>\n

Download Our Free Immunotherapy Guide<\/a><\/p>\n<\/div>\n

What Is the New Keytruda Injection for Mesothelioma?<\/h2>\n

Called Keytruda Qlex\u2122, the new injection is a faster way to receive this immunotherapy<\/a>. Keytruda Qlex is a subcutaneous <\/strong>immunotherapy\u00a0, meaning it\u2019s delivered under the skin instead of through a vein. It\u2019s combined with a special enzyme known as berahyaluronidase alfa-pmph that helps the medicine absorb more quickly and evenly.<\/p>\n

Unlike the traditional intravenous (IV) infusion, which requires patients to sit through a 30- to 40-minute procedure, subcutaneous Keytruda is given as a quick injection similar to a routine flu shot. Patients can receive their treatment in about 1 minute in their doctor\u2019s office instead of going to the hospital.<\/p>\n

Clinical studies have shown that this new injection delivers the same effectiveness<\/strong> as the traditional IV infusion.<\/p><\/blockquote>\n

By simplifying the administration process, Keytruda Qlex allows patients to focus more on recovery and quality of life while getting treatment to help their body fight this asbestos-related cancer.<\/p>\n

“We are committed to putting patients first, as we work relentlessly to discover new options that may help patients manage their treatment in a way that fits their needs<\/strong>,\u201d said Dr. Marjorie Green, senior vice president and head of oncology at Merck Research Laboratories.<\/p>\n

What the Keytruda Injection Means for Mesothelioma Patients<\/h3>\n

For patients with mesothelioma<\/a>, the new Keytruda injection makes a meaningful difference in day-to-day life, making treatment easier and less disruptive.<\/p>\n

By simplifying the delivery method, patients can spend less time in medical settings and focus more on daily life, recovery, and overall well-being.<\/p>\n

Benefits of Keytruda\u2019s subcutaneous approval for mesothelioma include:<\/strong><\/p>\n